Tagreed Alkaltham: Tranexamic Acid in PBM
Tagreed Alkaltham, Transfusion Medicine Lab Supervisor at KSMC, shared a post on LinkedIn:
“Tranexamic Acid (TXA) in PBM
Not a bleeding drug. A timing decision.
Tranexamic acid is often described as a medication for bleeding. But in Patient Blood Management, TXA is something else entirely. It is a decision about timing.
Bleeding doesn’t usually start out of control. It becomes uncontrolled when early structure is missed.
TXA works best in that narrow window when clot integrity is still protectable, and before bleeding escalates into loss of control.
Used early, TXA protects the newly forming clot from premature breakdown. Used late, it can only limit further damage.
From a PBM perspective, TXA is not about stopping blood loss after it happens. It’s about preventing escalation.
When given at the right time, TXA:
- preserves clot integrity
- reduces escalation
- lowers transfusion needs
Not because it replaces blood but because it protects the system from needing more of it.
From a Blood Bank Perspective:
TXA is not seen as a bleeding medication. It is seen as an early stabilizing decision.
When TXA is administered early, it often prevents the rapid cascade that follows uncontrolled bleeding: massive transfusion activation, sudden inventory pressure, and reactive decisions made under urgency rather than design.
Early TXA preserves more than clot integrity. It preserves options.
It allows the blood bank to respond within a controlled, balanced framework, instead of being pulled abruptly into crisis mode.
When TXA is delayed, the blood bank is rarely responding to bleeding alone, it is responding to escalation, narrowed choices, and loss of control.
PBM doesn’t fail when bleeding occurs. It fails when early decisions are delayed.
And TXA reminds us of a simple truth:
Timing is the intervention before blood is needed.”
Find more posts featuring Tagreed Alkaltham on Hemostasis Today.
-
Mar 31, 2026, 16:05Happy National Doctors’ Day to All Physicians Making a Difference – ASH
-
Mar 31, 2026, 16:03Robert Negrin: Strengthening Collaboration with NCI to Advance Hematology Research
-
Mar 31, 2026, 16:02Jim Hoffman: Does Multiomics Suggest LC PASC Patients Require Multiple Drugs to Correct Biochemical Dysregulation?
-
Mar 31, 2026, 15:59Seema Dawood: Blister Cell in G6PD Deficiency
-
Mar 31, 2026, 15:57Ney Carter Borges: Clopidogrel vs Aspirin in Long-Term Monotherapy
-
Mar 31, 2026, 15:57Join the Webinar on Immunoglobulin Access and Stewardship in the UK and Australia – ISBT
-
Mar 31, 2026, 15:55Hind El Azzazi: Successful Defense of My Medical Doctorate on Antiphospholipid Syndrome in Men
-
Mar 31, 2026, 15:54Rucha Patil: Honored to Speak at AIIMS Nagpur ToT Workshop on Non-Factor Therapy in Hemophilia A
-
Mar 31, 2026, 15:43Deepak Sudheendra: When the Clot Is Gone, but Symptoms Remain